CGON
CG Oncology, Inc. Common stock NASDAQ Listed Jan 25, 2024$68.01
After hrs
$67.79
-0.32%
Mkt Cap $5.7B
52w Low $21.00
89.4% of range
52w High $73.56
50d MA $65.41
200d MA $46.27
P/E (TTM)
-31.9x
EV/EBITDA
-20.0x
P/B
6.8x
Debt/Equity
0.0x
ROE
-21.4%
P/FCF
-24.2x
RSI (14)
—
ATR (14)
—
Beta
0.70
50d MA
$65.41
200d MA
$46.27
Avg Volume
1.2M
About
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BC…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | AMC | -0.61 | -0.51 | +16.4% | 58.80 | -2.9% | -1.8% | +3.0% | +4.7% | +2.7% | +5.2% | — |
| Nov 14, 2025 | AMC | -0.56 | -0.57 | -2.0% | 41.01 | +1.0% | +0.6% | +3.8% | +3.9% | -0.7% | +3.5% | — |
| Aug 8, 2025 | AMC | -0.49 | -0.54 | -10.2% | 24.85 | -0.4% | -3.6% | +0.4% | +6.6% | +4.5% | +3.4% | — |
| May 13, 2025 | AMC | -0.39 | -0.45 | -15.4% | 24.18 | -0.4% | -0.0% | +4.8% | +5.2% | +2.8% | +9.8% | — |
| Mar 28, 2025 | AMC | -0.41 | -0.48 | -17.1% | 26.42 | +1.5% | -7.3% | -16.5% | -15.8% | -29.1% | -34.9% | — |
| Aug 8, 2024 | AMC | -0.42 | -0.28 | +33.3% | 33.24 | +1.1% | +1.2% | -1.0% | +0.8% | -0.0% | +3.5% | — |
| May 9, 2024 | AMC | -0.35 | -0.36 | -2.9% | 30.02 | -0.0% | -5.1% | -13.9% | -9.0% | -6.7% | +3.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | RBC Capital | Maintains | Outperform → Outperform | — | $68.68 | $69.10 | +0.6% | -2.7% | -4.6% | -5.7% | -2.8% | -3.5% |
| Apr 17 | JP Morgan | Maintains | Overweight → Overweight | — | $66.34 | $67.61 | +1.9% | +10.7% | +6.1% | +8.3% | +5.3% | +5.4% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.55 | $68.56 | +1.5% | +3.3% | +2.0% | +1.5% | +0.2% | +0.2% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.11 | $55.79 | -0.6% | +4.8% | +2.9% | +7.9% | +9.7% | +7.6% |
| Feb 10 | Truist | Maintains | Buy → Buy | — | $51.08 | $51.37 | +0.6% | +3.9% | +4.8% | +1.1% | +0.8% | +5.5% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $54.69 | $55.03 | +0.6% | +4.5% | +2.1% | -1.6% | -2.5% | +0.7% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $53.07 | $53.20 | +0.2% | +3.1% | +3.1% | +7.7% | +5.2% | +1.4% |
| Jan 12 | Truist | Maintains | Buy → Buy | — | $54.20 | $55.31 | +2.0% | -0.9% | -3.0% | +2.4% | -2.1% | +1.0% |
| Nov 17 | RBC Capital | Maintains | Outperform → Outperform | — | $41.01 | $41.43 | +1.0% | +0.6% | +3.8% | +3.9% | -0.7% | +3.5% |
| Sep 26 | JP Morgan | Maintains | Overweight → Overweight | — | $36.48 | $37.46 | +2.7% | +2.9% | +7.1% | +10.4% | +8.2% | +9.2% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new executive at CGON is receiving $520,000 base salary plus 45% bonus potential, with equity grants vesting April 2026, signaling leadership continuity and standard compensation that shouldn't materially impact valuation.
Apr 13
8-K
CG Oncology, Inc. -- 8-K Filing
CG Oncology anticipates releasing interim data from its Phase III PIVOT-006 trial evaluating cretostimide for non-muscle invasive bladder cancer, a potential catalyst for investors monitoring the company's clinical pipeline progress.
Feb 27
Data updated apr 25, 2026 1:01am
· Source: massive.com